Alembic Pharmaceuticals has reported that its Vadodara facility passed the recent inspection by the United States Food and Drug Administrat...

In the year leading up to September 2023, the City of Greater Geelong transformed thousands of litres of used motor oil into durable public...

Indian equity markets experienced volatility, with the Nifty 50 extending its losing streak for four weeks. Escalating US-Iran hostilities ...

Fosun Pharma sold a 6% stake in Gland Pharma for ₹2,800 crore via a block deal, reducing its holding to 45.77%. Major buyers included Kotak...

Gland Pharma shares fell 3% after 1.22 crore shares changed hands in two block deals worth nearly Rs 5,818 crore. Promoter Fosun Pharma Ind...

Gland Pharma shares fell after a significant block deal involving Fosun Pharma Industrial. The company's VSEZ facility received zero USFDA ...

Fosun Pharma plans to divest 5% equity in Gland Pharma through a Rs 2,279.5 crore block deal at Rs 2,763 per share. Gland Pharma reported a...

The BSE Sensex ended at 76,944.28, lower by 12.99 points or 0.02%, as gains in IT, FMCG and select heavyweights helped limit the fall.

The Indian equity market experienced a positive turnaround on Tuesday, August 25, highlighted by the Nifty 50 making a robust recovery. Ant...

Indian equity markets closed largely unchanged on Friday, August 21, after a volatile trading session. Several companies, including Relianc...

Strides Pharma Science shares rise sharply on Thursday after the USFDA issued an Establishment Inspection Report (EIR) for its Bengaluru fa...

Aurobindo Pharma's US facility received a Voluntary Action Indicated classification. The US FDA closed its inspection of the Raleigh manufa...

Rail Vikas Nigam Limited stock shows early bullish reversal signs near 220. Experts suggest buying for a target above 250 in coming weeks. ...

FDA investigators have observed violations in sterilisation process to prevent microbial contamination and shortcomings in facility managem...

Dr.Reddy's Laboratories was issued a Form 483 which notifies the company's management of objectionable conditions, with 5 observations.

The company was responding to reports that the US health regulator has issued observations under Form 483 highlighting issues related to qu...

As per the USFDA, observations are made in Form 483 when investigators feel that practices in the facility are such that products may becom...